Pembrolizumab, non-small cell lung cancer, Treatment beyond failure of first-line treatment, Real-world study
Circulating mucosal-associated invariant T cells, CXCR6, Non-small cell lung cancer, Single-cell RNA-sequencing, Immunotherapy